Experiences of establishing an academic early phase clinical trials unit.
Brown SR et al. Clin Trials. 2017 May 1:1740774517710250. doi: 10.1177/1740774517710250. [Epub ahead of print].

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.
Harousseau JL et al. J Clin Oncol. 2017 May 19:JCO2017731331. doi: 10.1200/JCO.2017.73.1331. [Epub ahead of print].

Race colors transplantation utilization for multiple myeloma.
Majhail NS et al. Cancer. 2017 May 4. doi: 10.1002/cncr.30750. [Epub ahead of print].

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Schriber JR et al. Cancer. 2017 May 4. doi: 10.1002/cncr.30747. [Epub ahead of print].

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P et al. Ann Oncol. 2017 May 24. doi: 10.1093/annonc/mdx160. [Epub ahead of print].

Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.
Dutta AK et al. Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14649. [Epub ahead of print].

The safety of daratumumab for the treatment of multiple myeloma.
Cejalvo MJ et al. Expert Opin Drug Saf. 2017 Jun;16(6):753-760. doi: 10.1080/14740338.2017.1328053. Epub 2017 May 22.

Daratumumab for the treatment of multiple myeloma.
Touzeau C et al. Expert Opin Biol Ther. 2017 May 2:1-7. doi: 10.1080/14712598.2017.1322578. [Epub ahead of print].

Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T et al. Oncotarget. 2017 May 16;8(20):34001-34017. doi:10.18632/oncotarget.16987.

How do I work up pretransfusion samples containing anti-CD38?
Anani WQ et al. Transfusion. 2017 May 5. doi: 10.1111/trf.14144. [Epub ahead of print].

Recognition of early mortality in multiple myeloma by a prediction matrix.
Terebelo H et al. Am J Hematol. 2017 May 24. doi: 10.1002/ajh.24796. [Epub ahead of print].

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ et al. J Clin Oncol. 2017 May 25:JCO2017722447. doi: 10.1200/JCO.2017.72.2447. [Epub ahead of print].

Music Therapy for Symptom Management after Autologous Stem Cell Transplantation: Results from a Randomized Study.
Bates D et al. Biol Blood Marrow Transplant. 2017 May 19. pii: S1083-8791(17)30462-7. doi: 10.1016/j.bbmt.2017.05.015. [Epub ahead of print].

Cancer risks in a population-based study of 70,570 agricultural workers: results from the Canadian census health and Environment cohort (CanCHEC).
Kachuri L et al. BMC Cancer. 2017 May 19;17(1):343. doi: 10.1186/s12885-017-3346-x.

Utilizing next-generation sequencing in the management of multiple myeloma.
Lionetti M et al. Expert Rev Mol Diagn. 2017 May 19. doi: 10.1080/14737159.2017.1332996. [Epub ahead of print].

Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement.
Mailankody S et al. JAMA. 2017 May 18. doi: 10.1001/jama.2017.5784. [Epub ahead of print].

New Treatment Options for the Management of Multiple Myeloma.
Kumar SK. J Natl Compr Canc Netw. 2017 May;15(5S):709-712.

Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China.
Li X et al. Acta Haematol. 2017 May 18;137(4):209-213. doi: 10.1159/000468973. [Epub ahead of print].

How is patient care for multiple myeloma advancing?
Genadieva Stavric S et al. Expert Rev Hematol. 2017 May 19:1-11. doi: 10.1080/17474086.2017.1326814. [Epub ahead of print].

Multiple Myeloma Mimics Bone Metastasis From a Rectal Adenocarcinoma.
Kim IK et al. Ann Coloproctol. 2017 Apr;33(2):70-73. doi: 10.3393/ac.2017.33.2.70. Epub 2017 Apr 28.

Vitamin D and plasma cell dyscrasias: reviewing the significance.
Burwick N.Ann Hematol. 2017 May 13. doi: 10.1007/s00277-017-3
016-8. [Epub ahead of print].

Risk and impact of tuberculosis in patients with multiple myeloma.
Tsai CK et al. Leuk Lymphoma. 2017 May 9:1-9. doi: 10.1080/10428194.2017.1312369. [Epub ahead of print].

Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore.
Abid MB et al. Bone Marrow Transplant. 2017 May 8. doi: 10.1038/bmt.2017.77. [Epub ahead of print].

Novel investigational drugs active as single agents in multiple myeloma.
D’Agostino M et al. Expert Opin Investig Drugs. 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8.